Literature DB >> 16333616

Gastric antibacterial efficiency is different for pepsin A and C.

Sören Schreiber1, Roland Bücker, Claudia Groll, Marina Azevedo-Vethacke, Peter Scheid, Sören Gatermann, Christine Josenhans, Sebastian Suerbaum.   

Abstract

The gastric lumen represents a bactericidal barrier, whose major components are an acidic pH and a family of isoenzymes of the gastric aspartate protease, pepsin. To evaluate whether specific pepsins are specialized in antibacterial protection, we tested their effects on the gastric pathogen Helicobacter pylori. In a recent study we found pepsin to affect the motility of the bacteria, one of its most important virulence factors. We were able to show that the antibacterial effect of pepsin occurs in two phases: rapid loss of motility and subsequent destruction. In the present study we used the rapid pepsin-induced bacterial immobilization as a marker of antibacterial efficiency. The proteolytic activity of different pepsins was normalized to values between 2 and 200 U/ml in the hemoglobin degradation test of Anson, performed at pH 2 and 5. We found that pepsin C completely inactivates H. pylori at proteolytic activities of 2 (pH 5) and 20 (pH 2) U/ml. In contrast, the activities of pepsin A and chymosin required to affect Helicobacter motility were ten times higher.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16333616     DOI: 10.1007/s00203-005-0053-9

Source DB:  PubMed          Journal:  Arch Microbiol        ISSN: 0302-8933            Impact factor:   2.552


  2 in total

1.  Specific therapeutic schemes of omeprazole affect the orientation of Helicobacter pylori.

Authors:  Marina Azevedo-Vethacke; Désirée Garten; Claudia Groll; Sören Schreiber
Journal:  Antimicrob Agents Chemother       Date:  2009-06-01       Impact factor: 5.191

2.  Helicobacter pylori colonization critically depends on postprandial gastric conditions.

Authors:  Roland Bücker; Marina Azevedo-Vethacke; Claudia Groll; Désirée Garten; Christine Josenhans; Sebastian Suerbaum; Sören Schreiber
Journal:  Sci Rep       Date:  2012-12-18       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.